Both in Biotechnology
Pluri vs Estrella Immunopharma
Over the past year PLUR returned −65.3% and ESLA returned −80.6%; their daily moves had a correlation of 0.11.
PLUR −65.3% ESLA −80.6%Growth of $1, one year, split-adjusted
| Metric | PLUR | ESLA |
|---|---|---|
| Price | $1.23 | $0.4435 |
| Market cap | $16.6M | $19.3M |
| Today | −3.15% | +6.10% |
| 1 month | +24.2% | +3.4% |
| 6 months | −62.7% | −65.9% |
| Year to date | −58.9% | −71.6% |
| 1 year | — | −85.5% |
| Revenue growth (YoY) | −15.8% | — |
| Gross margin | 58.5% | — |
| Net margin | −1755.2% | — |
| P/E (TTM) | — | — |
| Price / sales | 16.4× | — |
| Net cash | -$23.9M | $146.7K |
| Dividend yield | — | — |
| Volatility (60d) | 81.3% | 201.6% |
| Short % of float | 0.3% | 4.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).